Ann: Volpara DENSE trial results published, page-9

This was a game changer in terms of validity of the Volpara product. The market didn't think so. This should have reached new highs, however it didn't.

Many investors think like me. This is an overheated stock that lacks the fundamentals to support its quality product. They may need to rethink how they advise the market of news that has the potential to change its industry in its favour.

Sales projections were missing and as were complementing AI solutions. Maybe management will get it right next time. Today's reaction was the market's verdict.